Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer

Gut

Volumn 52, Issue 11, 2003, Pages 1598-1601

  Shpitz, B ^a   Klein, E ^a   Buklan, G ^a   Neufeld, D ^a   Nissan, A ^b   Freund, H R ^b   Grankin, M ^a   Bernheim, J ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCENDING COLON; CANCER PREVENTION; CELL DENSITY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DESCENDING COLON; DRUG EFFECT; DRUG EFFICACY; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE CRYPT; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PRECANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; COLON; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTESTINAL MUCOSA; INTESTINE, LARGE; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; TIME FACTORS;

EID: 0242361159     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.11.1598     Document Type: Article

References (34)

1. Cancer statistics 2002. CA Cancer J Clin 2002;52:23-47.
2. Giovancucci E. The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 1999;53:303-8.
3. Jänne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
4. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 2002;94:950-63.
5. Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991;51:1564-7.
6. Wargovich MJ, Jimenez A, McKee K, et al. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 2000;21:1149-55.
7. Roncucci L, Pedroni M, Vaccina F, et al. Aberrant crypt foci in colorectal carcinogenesis. Cell Prolif 2000;33:1-18.
8. Roncucci L, Stamp D, Medline A, et al. Identification and quantification of aberrant crypt foci and microadenomas in human colons. Hum Pathol 1991;22:287-94.
9. Smith AJ, Stern HS, Penner M, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994;54:5527-30.
10. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.
11. Shpitz B, Bomstein Y, Mekori Y, et al. Aberrant crypt foci in human colons: distribution and histopathologic characteristics. Hum Pathol 1998;29:469-75.
12. Wargovich MJ, Chen CD, Harris C, et al. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 1995;60:515-19.
13. Shpitz B, Bomstein Y, Kariv N, et al. Chemopreventive effect of aspirin on growth of aberrant crypt foci in rats. Int J Colorect Dis 1998;13:169-72.
14. Barnes CJ, Hardman E, Cameron IL, et al. Aspirin, but not sodium salicylate, indomethacin or nabumetone reversibly suppresses 1,2-dimethylhidrazine-induced colonic aberrant crypt foci in rats. Dig Dis Sci 1997;42:920-6.
15. Bak AW, McKnight W, Li P, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998;62:PL367-73.
16. Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-7.
17. Mereto E, Frencia L, Ghia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colons by 1,2-dimethylhidrazine. Cancer Lett 1994;76:5-9.
18. Di Gregorio C, Losi L, Fante R, et al. Histology of ACF in human colons. Histopathology 1997;30:328-34.
19. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001;85:265-71.
20. Calverley DC. Thromboembolic disease and anticoagulation in the elderly. Clin Geriatr Med 2001;17:31-48.
21. International Stroke Collaborative Group. The international stroke trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither, among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
22. Greenberg ER, Baron JA. Reduced risk of large bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912-16.
23. Giovancucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241.
24. Rao CV, Hirose Y, Indranie C, et al. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-33.
25. Lasko CM, Good CK, Adam J, et al. Energy restriction modulates the development of advanced preneoplastic lesions depending on the level of fat in the diet. Nutr Cancer 1999;33:69-75.
26. Zalantai A, Lapis K, Szende B, et al. Wheat germ extract inhibits experimental colon carcinogenesis in F-344 rats. Carcinogenesis 2001;22:1649-52.
27. Katayama M, Yoshimi N, Yamada Y. Preventive effect of fermented brown rice and rice bran against colon carciogenesis in male F344 rats. Oncol Rep 2002;9:817-22.
28. Pereira MA. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs. Adv Exp Med Biol 1999;470:55-63.
29. 2 levels in rat colon. Carcinogenesis 1999;20:425-30.
30. Ruffin IV MT, Krishnan K, Rock CL, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997;89:1152-60.
31. Roy HK, Karolski WJ, Ratashak A. Distal bowel selectivity in the chemopreventionn of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer 2001;92:609-15.
32. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effect of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999;190:445-50.
33. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
34. Ota S, Bamba H, Kato A, et al. COX-2, prostanoids and colon cancer. Alliment Pharmacol Ther 2002;16(suppl 2):102-6.